Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): An open-label, single-arm phase 2 study

The Lancet Oncology

Volumn 13, Issue 4, 2012, Pages 375-384

  Pierga, Jean Yves ^a,b   Petit, Thierry ^c   Delozier, Thierry ^d   Ferrero, Jean Marc ^e   Campone, Mario ^f   Gligorov, Joseph ^g   Lerebours, Florence ^a   Roché, Henri ^h   Bachelot, Thomas ⁱ   Charafe Jauffret, Emmanuelle ^j,l   Pavlyuk, Maria ^k   Kraemer, Sandrine ^k   Bidard, François Clément ^j   Viens, Patrice ^j,l  

^a INSTITUT CURIE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE PAUL STRAUSS   (France)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f Institut de cancerologie de l'Ouest Rene Gauducheau   (France)

^g UNIVERSITÉ PARIS EST   (France)

^h INSTITUT CLAUDIUS REGAUD   (France)

ⁱ CENTRE LÉON BÉRARD   (France)

^j INSTITUT PAOLI CALMETTES   (France)

^k Neuilly sur Seine   (France)

^l AIX MARSEILLE UNIVERSITY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ABDOMINAL PAIN; ABSCESS; ADJUVANT THERAPY; ADULT; ALOPECIA; ANAL ABSCESS; ANEMIA; ANOREXIA; APPENDICITIS; ARTHRALGIA; ARTICLE; ASTHENIA; AXILLARY LYMPH NODE; AXILLARY NODE DISSECTION; BACKACHE; BLEEDING; BONE MARROW APLASIA; BONE MARROW DEPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHEVALIER CLASSIFICATION; CIRCULATING ENDOTHELIAL CELL; CIRCULATING TUMOR CELL; CLINICAL CLASSIFICATION; COLITIS; CONJUNCTIVITIS; CONSTIPATION; DIARRHEA; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPEPSIA; ENDOTHELIUM CELL; EPISTAXIS; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; FRANCE; GASTROESOPHAGEAL REFLUX; GINGIVA BLEEDING; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; HYPERTHERMIA; INFLAMMATORY BREAST CANCER; JUGULAR VEIN THROMBOSIS; LACRIMATION; LEUKOPENIA; LOADING DRUG DOSE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALAISE; MASTECTOMY; METRORRHAGIA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; ONYCHOLYSIS; PREOPERATIVE TREATMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEINURIA; RHINOPHARYNGITIS; SATALOFF CLASSIFICATION; SEPTIC SHOCK; SEROMA; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TONSILLITIS; TREATMENT DURATION; TREATMENT RESPONSE; VEIN THROMBOSIS; WOUND HEALING IMPAIRMENT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MIDDLE AGED; NAUSEA; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEUTROPENIA; POSTOPERATIVE CARE; RECEPTOR, ERBB-2;

EID: 84859158912     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70049-9     Document Type: Article

References (48)

1. Dawood S, Ueno NT, Valero V, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 2011, 117:1819-1826.
2. Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH Epidemiology of inflammatory breast cancer (IBC). Breast Dis 2005-2006, 22:9-23.
3. Lerebours F, Bieche I, Lidereau R Update on inflammatory breast cancer. Breast Cancer Res 2005, 7:52-58.
4. Dushkin H, Cristofanilli M Inflammatory breast cancer. J Natl Compr Canc Netw 2011, 9:233-240.
5. Cristofanilli M, Valero V, Buzdar AU, et al. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer 2007, 110:1436-1444.
6. Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S, Suter T Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol 2008, 19:1530-1539.
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672. the Herceptin Adjuvant (HERA) Trial Study Team.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
9. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
10. Baselga J, Semiglazov V, Manikhas GM, et al. Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (NeOAdjuvant Herceptin) phase III trial. Eur J Cancer Suppl 2007, 5:193. (abstr 2030).
11. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials. Anticancer Drugs 2011, 22:128-135.
12. Wildiers H, Neven P, Christiaens MR, et al. Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Ann Oncol 2011, 22:588-594.
13. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007, 13:228-233.
14. Ferrara N Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
15. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009, 27:4966-4972.
16. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
17. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29:1252-1260.
18. Brufsky A, Bondarenko I, Smirnov V, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res 2009, 69(suppl 3). abstr 42.
19. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006, 24:769-777.
20. Pegram M, Yeon C, Durna LN, et al. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 2004, 88(suppl 1). abstr 3039.
21. Pegram M, Chan D, Dichmann R, et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat 2006, 100(suppl 1). abstr 301.
22. Rack BK, Schindlbeck C, Andergassen A, et al. Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: the SUCCESS trial. Proc Am Soc Clin Oncol 2010, 28(suppl). abstr 1003.
23. Pierga JY, Bidard FC, Mathiot C, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008, 14:7004-7010.
24. Bidard FC, Mathiot C, Degeorges A, et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010, 21:1765-1771.
25. Pierga J-Y, Hajage D, Bachelot T, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2011, published online June 3. 10.1093/annonc/mdr263.
26. Valero V, Buzdar AU, Hortobagyi GN Inflammatory breast cancer: clinical features and the role of multimodality therapy. Breast J 1996, 2:345-352.
27. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145. the American Society of Clinical Oncology, the College of American Pathologiststhe College of American Pathologists.
28. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995, 180:297-306.
29. Chevallier B, Bastit P, Graic Y, et al. The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer 1993, 67:594-601.
30. Sahoo S, Lester SC Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med 2009, 133:633-642.
31. Penault-Llorca F, Abrial C, Raoelfils I, et al. Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol 2008, 39. abstr 1221.
32. Riethdorf S, Müller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010, 16:2634-2645.
33. Viens P, Palangié T, Janvier M, et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer 1999, 81:449-456.
34. Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011, 22:515-523.
35. Viens P, PalangieT, Ferrero J-M, et al. 5FU-docetaxel maintenance regimen after high-dose of pre-operative epirubicin-cyclophosphamide for treatment of inflammatory breast cancer: results of the FNCLCC-Pegase 07 trial. 32nd Annual San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 9-13, 2009: abstr 2081.
36. Dawood S, Gong Y, Broglio K, et al. Trastuzumab in primary inflammatory breast cancer (IBC): high pathological response rates and improved outcome. Breast J 2010, 16:529-532.
37. Untch M, Fasching PA, Konecny GE, et al. Abstract P1-11-03: pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy. Three year median follow-up data of the TECHNO trial. Cancer Res 2011, 70(suppl 2). abstr S3-1.
38. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
39. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23:792-799.
40. Hurvitz S, Pegram M, Lin L, et al. Final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. Cancer Res 2010, 69. abstr 6094.
41. von Minckwitz G, Eidtmann H, Loibl S, et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2011, 22:301-306.
42. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640.
43. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:25-32.
44. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.
45. Guarneri V, Frassoldati A, Bottini A, et al. Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 507.
46. Blackwell K, Burstein H, Sledge G, et al. Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. Cancer Res 2010, 69. abstr 61.
47. Callahan RD, Patel R, Chan D, et al. Phase II trial of presurgical treatment with trastuzumab (H) or lapatinib (Ty) or the combination of trastuzumab and lapatinib (H+Ty), followed by six cycles of docetaxel (T) and carboplatin (C) with trastuzumab (TCH) or lapatinib (TCTy) or the combination of trastuzumab and lapatinib (TCHTy) in patients with HER2+ breast cancer. 34th San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 6-10, 2011. Abstract P1-11-12.
48. Costa SD, Loibl S, Kaufmann M, et al. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. J Clin Oncol 2010, 28:83-91.